Verger Antoine, Arbizu Javier, Law Ian
Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Lorraine University, Nancy, France -
IADI, INSERM, Lorraine University, Nancy, France -
Q J Nucl Med Mol Imaging. 2018 Sep;62(3):254-266. doi: 10.23736/S1824-4785.18.03092-3. Epub 2018 Apr 26.
Positron emission tomography (PET) using radiolabeled amino-acids was recently recommended by the Response Assessment in Neuro-Oncology (RANO) working group as an additional tool in the diagnostic assessment of brain tumors. The aim of this review is to summarize available literature data on the role of amino-acid PET imaging in high-grade gliomas (HGGs), with regard to diagnosis, treatment planning and follow-up of these tumors. Indeed, amino-acid PET applications are multiple throughout the evolution of HGGs. However, certain limitations such as lack of specificity, uncertain value for grading and prognostication or the limited data for treatment monitoring should to be taken into account, the latter of which are further developed in this review. Notwithstanding these limitations, amino-acid PET is becoming increasingly accessible in many nuclear medicine centers. Larger prospective cohort prospective studies are thus needed in order to increase the clinical value of this modality and enable its extended use to the largest number of patients.
正电子发射断层扫描（PET）使用放射性标记氨基酸，最近被神经肿瘤学反应评估（RANO）工作组推荐为脑肿瘤诊断评估中的一种辅助工具。本综述的目的是总结关于氨基酸PET成像在高级别胶质瘤（HGG）中的作用的现有文献数据，涉及这些肿瘤的诊断、治疗计划和随访。事实上，在HGG的整个病程中，氨基酸PET有多种应用。然而，应考虑到某些局限性，如缺乏特异性、分级和预后价值不确定或治疗监测数据有限，本综述将进一步探讨后者。尽管有这些局限性，但氨基酸PET在许多核医学中心越来越容易获得。因此，需要进行更大规模的前瞻性队列研究，以提高这种检查方式的临床价值，并使其能够应用于更多患者。
